echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > NICE UK approves Roche's PD-L1 single anti-Tecentriq treatment for triple-negative breast cancer after offering big discount

    NICE UK approves Roche's PD-L1 single anti-Tecentriq treatment for triple-negative breast cancer after offering big discount

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    The National Institute of Health and Clinical Excellence (NICE) has approved its immunotherapy PD-L1 monoantiticriq (atezolizumab) for the treatment of triple-negative breast cancer (TNBC) patients after Roche offered a significant discount to the NHS in the UKAT THE END OF LAST YEAR, NICE DID NOT RECOMMEND TECENTRIQ BECAUSE THE DRUG WAS NOT COST-EFFECTIVE ON TNBC AND COULD NOT EVEN EXTEND ITS LIFEAT THE TIME, NICE ADDED THAT ROCHE'S PD-L1 MONOAB "IS NOT POTENTIALLY COST-EFFECTIVE AT CURRENT PRICES AND THERE IS NO CLEAR EVIDENCE THAT FURTHER TRIALS CAN ADDRESS THE UNCERTAINTY OF PD-L1 MONOANTINOS"Under NICE's advice, Roche offered confidential discounts to the NHSTNBC is a aggressive form of breast cancer with few other treatment options than surgery, radiotherapy and chemotherapyTNBC tumors also lack estrogen, progesterone and HER2 receptors, making it impossible to use drugs that target these biomarkersThe recommendation is based on the results of the IMpassion130 3 study, in which Tecentriq and Celgene's Abraxane (nab-yew alcohol) had a progression-free lifetime of 2.5 months and a total lifetime of approximately 9.5 monthsNICE now recommends Tecentriq, along with Abraxane, for metastatic TNBC patients who have not yet received chemotherapy treatment and are unable to operateRival Merck's PD-1 monoantibuta (pembrolizumab) did not show the same effect on TNBC
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.